A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

NCT06514794 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

125

Enrollment

INDUSTRY

Sponsor class

Conditions

T-cell Acute Lymphoblastic Leukemia
Lymphoblastic Lymphoma

Interventions

BIOLOGICAL: WU-CART-007

Sponsor

Wugen, Inc.